Epstein Barr Virus Volume 2 One Herpes Virus: Many Diseases /
| Autor Corporativo: | |
|---|---|
| Otros Autores: | |
| Formato: | eBook |
| Lenguaje: | English |
| Publicado: |
Cham :
Springer International Publishing : Imprint: Springer,
2015.
|
| Edición: | 1st ed. 2015. |
| Colección: | Current Topics in Microbiology and Immunology,
391 |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1007/978-3-319-22834-1 |
Tabla de Contenidos:
- Preface
- EBV latency
- Chap. 1. EBNA1 – Lori Frappier, University of Toronto, Canada
- Chap. 2. EBNA2 and its coactivator EBNA-LP – Bettina Kempkes, Helmholtz Center Munich, Germany, and Paul D. Ling, Baylor College of Medicine, Houston, USA
- Chap. 3. The EBNA3 family: two oncoproteins and a tumour suppressor that are central to the biology of EBV in B cells– Martin J. Allday, Quentin Bazot and Robert E. White, Imperial College London, UK. Chap. 4. The latent membrane protein 1 (LMP1) – Arnd Kieser and Kai R. Sterz, Helmholtz Center Munich, Germany. Chap. 5. Latent membrane protein 2 (LMP2) – Osman Cen and Richard Longnecker, Northwestern University, Chicago, USA. Chap. 6. EBV non-coding RNAs – Rebecca L. Skalsky and Bryan R. Cullen, Duke University, Durham, USA
- E. Lytic EBV infection
- 7. Viral entry – Liudmila S. Chesnokova, Ru Jiang1 and Lindsey M. Hutt-Fletcher, Louisiana State University, Shreveport, USA
- Chap. 8. Epstein Barr virus lytic cycle reactivation – Jessica McKenzie and Ayman El-Guindy, Yale University, New Haven, USA
- Immune responses to EBV
- Chap. 9. Innate immune recognition of EBV – Anna Lünemann and David Nadal, University of Zürich, Switzerland and Martin Rowe, University of Birmingham, UK
- Chap. 10. Epstein-Barr virus specific humoral immune responses in health and disease – Jaap M. Middeldorp, VU Medical Center, Amsterdam, The Netherlands
- Chap. 11. T cell responses to EBV – Andrew D. Hislop and Graham S. Taylor, University of Birmingham, UK
- Chap. 12. Immune evasion by Epstein Barr virus – Maaike E. Ressing, Michiel van Gent, Anna M. Gram, Marjolein Hooykaas, Sytse Piersma and Emmanuel Wiertz, Utrecht Medical Center, The Netherlands
- Animal models of EBV infection
- Chap. 13. Non-human primate lymphocryptoviruses: past, present, and future– Janine Mühe and Fred Wang, Harvard University, Boston, USA. Chap.14. EBV infection of mice with reconstituted human immune system components – Christian Münz, University of Zürich, Switzerland
- Therapy of EBV associated diseases
- Chap. 15. Adoptive T cell immunotherapy – Stephen Gottschalk and Cliona Rooney, Baylor College of Medicine, Houston, USA
- Chap. 16. The Development of Prophylactic and Therapeutic EBV Vaccines – Corey Smith and Rajiv Khanna, Queensland Institute of Medical Research, Brisbane, Australia
- Chap. 17. The biology and clinical utility of EBV monitoring in blood– Jennifer Kanakry and Richard Ambinder, Johns Hopkins University, Baltimore, USA
- Index.